 Emily Su
Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Placenta | 20 | 2025 | 780 | 5.110 |
Why?
| | Fetal Growth Retardation | 14 | 2025 | 587 | 4.950 |
Why?
| | Endothelial Cells | 10 | 2023 | 869 | 2.300 |
Why?
| | Estrogen Receptor beta | 6 | 2012 | 43 | 1.760 |
Why?
| | Umbilical Arteries | 3 | 2024 | 52 | 1.670 |
Why?
| | Neovascularization, Physiologic | 4 | 2021 | 194 | 1.530 |
Why?
| | Pregnancy | 35 | 2025 | 7190 | 1.340 |
Why?
| | Extracellular Matrix | 2 | 2025 | 553 | 1.180 |
Why?
| | Hypertension | 10 | 2025 | 1263 | 1.120 |
Why?
| | Hypertension, Pregnancy-Induced | 5 | 2024 | 67 | 1.100 |
Why?
| | Premature Birth | 6 | 2024 | 380 | 1.090 |
Why?
| | Pregnancy Complications, Cardiovascular | 8 | 2025 | 83 | 1.070 |
Why?
| | Aryl Hydrocarbon Receptor Nuclear Translocator | 2 | 2019 | 19 | 1.040 |
Why?
| | Antihypertensive Agents | 8 | 2025 | 510 | 1.010 |
Why?
| | Endometriosis | 6 | 2012 | 57 | 0.950 |
Why?
| | Chorionic Villi | 2 | 2024 | 25 | 0.850 |
Why?
| | Integrin alphaVbeta3 | 1 | 2022 | 20 | 0.760 |
Why?
| | Cell Movement | 4 | 2021 | 965 | 0.720 |
Why?
| | Proteome | 2 | 2025 | 518 | 0.690 |
Why?
| | Vascular Endothelial Growth Factor Receptor-1 | 3 | 2022 | 74 | 0.690 |
Why?
| | Otoacoustic Emissions, Spontaneous | 1 | 2020 | 7 | 0.670 |
Why?
| | Acoustic Impedance Tests | 1 | 2020 | 13 | 0.670 |
Why?
| | Prostaglandins | 2 | 2011 | 94 | 0.630 |
Why?
| | Neovascularization, Pathologic | 2 | 2019 | 286 | 0.630 |
Why?
| | Pre-Eclampsia | 6 | 2024 | 204 | 0.600 |
Why?
| | Artificial Intelligence | 1 | 2024 | 365 | 0.590 |
Why?
| | Proteomics | 2 | 2025 | 1195 | 0.590 |
Why?
| | Progesterone | 4 | 2010 | 255 | 0.590 |
Why?
| | Uveomeningoencephalitic Syndrome | 1 | 2019 | 8 | 0.590 |
Why?
| | Fetus | 5 | 2023 | 803 | 0.580 |
Why?
| | 17-Hydroxysteroid Dehydrogenases | 2 | 2010 | 4 | 0.580 |
Why?
| | Panuveitis | 1 | 2019 | 8 | 0.580 |
Why?
| | Estrogens | 2 | 2012 | 380 | 0.580 |
Why?
| | Adalimumab | 1 | 2019 | 55 | 0.570 |
Why?
| | Female | 48 | 2025 | 78271 | 0.560 |
Why?
| | Pregnancy Outcome | 7 | 2024 | 476 | 0.490 |
Why?
| | Benzo(a)pyrene | 1 | 2016 | 8 | 0.490 |
Why?
| | Cyclooxygenase 2 | 3 | 2016 | 165 | 0.480 |
Why?
| | Vascular Endothelial Growth Factor A | 6 | 2022 | 557 | 0.470 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2016 | 60 | 0.470 |
Why?
| | Endothelium, Vascular | 5 | 2018 | 965 | 0.460 |
Why?
| | Signal Transduction | 5 | 2019 | 5226 | 0.430 |
Why?
| | Humans | 51 | 2025 | 144759 | 0.430 |
Why?
| | Endometrium | 4 | 2012 | 61 | 0.410 |
Why?
| | Stromal Cells | 4 | 2025 | 124 | 0.400 |
Why?
| | Fibronectins | 2 | 2025 | 136 | 0.400 |
Why?
| | Reproduction | 2 | 2012 | 207 | 0.400 |
Why?
| | Umbilical Cord | 1 | 2013 | 91 | 0.380 |
Why?
| | Cell Proliferation | 2 | 2018 | 2496 | 0.380 |
Why?
| | Stillbirth | 1 | 2013 | 77 | 0.370 |
Why?
| | Fetal Diseases | 1 | 2013 | 191 | 0.340 |
Why?
| | Birth Weight | 4 | 2025 | 522 | 0.330 |
Why?
| | Endothelium | 1 | 2011 | 119 | 0.330 |
Why?
| | Infant, Newborn | 13 | 2025 | 6429 | 0.330 |
Why?
| | Ultrasonography, Doppler | 2 | 2024 | 126 | 0.300 |
Why?
| | Women's Health | 1 | 2012 | 310 | 0.300 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2007 | 269 | 0.300 |
Why?
| | Adult | 19 | 2025 | 40449 | 0.290 |
Why?
| | Estradiol | 3 | 2011 | 533 | 0.280 |
Why?
| | Promegestone | 1 | 2007 | 33 | 0.260 |
Why?
| | Infant, Small for Gestational Age | 2 | 2025 | 109 | 0.260 |
Why?
| | Postpartum Period | 3 | 2024 | 365 | 0.260 |
Why?
| | Up-Regulation | 3 | 2019 | 851 | 0.230 |
Why?
| | Fetal Development | 2 | 2023 | 299 | 0.230 |
Why?
| | Estrogen Receptor alpha | 3 | 2012 | 161 | 0.230 |
Why?
| | Dystonia | 1 | 2025 | 28 | 0.230 |
Why?
| | Pregnancy Trimester, Third | 1 | 2025 | 115 | 0.220 |
Why?
| | Chronic Disease | 7 | 2025 | 1813 | 0.220 |
Why?
| | Placental Circulation | 2 | 2017 | 70 | 0.220 |
Why?
| | Labetalol | 1 | 2024 | 6 | 0.210 |
Why?
| | Nifedipine | 1 | 2024 | 27 | 0.210 |
Why?
| | Hip Fractures | 1 | 2025 | 84 | 0.210 |
Why?
| | Case-Control Studies | 4 | 2021 | 3604 | 0.210 |
Why?
| | Hypotension | 1 | 2025 | 126 | 0.210 |
Why?
| | Uterus | 2 | 2017 | 226 | 0.200 |
Why?
| | Delivery, Obstetric | 1 | 2024 | 160 | 0.190 |
Why?
| | Running | 1 | 2025 | 228 | 0.190 |
Why?
| | Integrin alpha5beta1 | 1 | 2022 | 9 | 0.190 |
Why?
| | Breast Feeding | 2 | 2024 | 448 | 0.190 |
Why?
| | Gestational Age | 5 | 2024 | 975 | 0.190 |
Why?
| | Cost of Illness | 1 | 2025 | 321 | 0.190 |
Why?
| | Regional Blood Flow | 2 | 2017 | 514 | 0.190 |
Why?
| | Pregnancy in Diabetics | 1 | 2024 | 121 | 0.190 |
Why?
| | Cells, Cultured | 5 | 2021 | 4154 | 0.180 |
Why?
| | Cannabidiol | 1 | 2024 | 136 | 0.180 |
Why?
| | Epoprostenol | 2 | 2016 | 131 | 0.180 |
Why?
| | Extracellular Matrix Proteins | 1 | 2023 | 158 | 0.180 |
Why?
| | Dronabinol | 1 | 2024 | 247 | 0.180 |
Why?
| | Furin | 1 | 2021 | 13 | 0.170 |
Why?
| | Otoscopy | 1 | 2020 | 8 | 0.170 |
Why?
| | Trophoblasts | 2 | 2021 | 216 | 0.170 |
Why?
| | Drug Monitoring | 1 | 2024 | 395 | 0.170 |
Why?
| | Reperfusion Injury | 1 | 2023 | 300 | 0.160 |
Why?
| | New Zealand | 1 | 2020 | 54 | 0.160 |
Why?
| | Receptors, Virus | 1 | 2021 | 96 | 0.160 |
Why?
| | Steroidogenic Factor 1 | 2 | 2012 | 12 | 0.160 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 94 | 0.160 |
Why?
| | Serine Endopeptidases | 1 | 2021 | 128 | 0.160 |
Why?
| | Receptors, Progesterone | 3 | 2012 | 356 | 0.160 |
Why?
| | Fibroblasts | 1 | 2025 | 1034 | 0.160 |
Why?
| | Cohort Studies | 4 | 2024 | 5960 | 0.150 |
Why?
| | RNA Interference | 3 | 2011 | 476 | 0.150 |
Why?
| | Models, Biological | 2 | 2017 | 1821 | 0.150 |
Why?
| | Triamcinolone | 1 | 2019 | 13 | 0.150 |
Why?
| | Parkinson Disease | 1 | 2025 | 600 | 0.140 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2018 | 85 | 0.140 |
Why?
| | Mycophenolic Acid | 1 | 2019 | 120 | 0.140 |
Why?
| | Hypertension, Pulmonary | 2 | 2022 | 1980 | 0.140 |
Why?
| | Remission Induction | 1 | 2019 | 307 | 0.140 |
Why?
| | Hospitalization | 2 | 2025 | 2433 | 0.130 |
Why?
| | Prenatal Exposure Delayed Effects | 1 | 2024 | 675 | 0.130 |
Why?
| | Headache | 1 | 2019 | 150 | 0.130 |
Why?
| | Fluorescein Angiography | 1 | 2019 | 189 | 0.130 |
Why?
| | Gene Expression Regulation | 3 | 2012 | 2608 | 0.130 |
Why?
| | Blood Pressure | 4 | 2025 | 1769 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2011 | 983 | 0.130 |
Why?
| | Fetal Blood | 2 | 2017 | 342 | 0.130 |
Why?
| | Research Design | 1 | 2023 | 1135 | 0.130 |
Why?
| | Systems Biology | 1 | 2017 | 72 | 0.130 |
Why?
| | Pluripotent Stem Cells | 1 | 2017 | 84 | 0.120 |
Why?
| | Morphogenesis | 1 | 2017 | 173 | 0.120 |
Why?
| | Tomography, Optical Coherence | 1 | 2019 | 271 | 0.120 |
Why?
| | Feasibility Studies | 1 | 2020 | 1095 | 0.120 |
Why?
| | Mental Disorders | 1 | 2025 | 1168 | 0.120 |
Why?
| | Organoids | 1 | 2017 | 141 | 0.120 |
Why?
| | Epigenesis, Genetic | 2 | 2012 | 684 | 0.120 |
Why?
| | Lab-On-A-Chip Devices | 1 | 2016 | 60 | 0.120 |
Why?
| | Substance-Related Disorders | 1 | 2025 | 1094 | 0.120 |
Why?
| | Drug Therapy, Combination | 1 | 2019 | 1047 | 0.120 |
Why?
| | Acute Kidney Injury | 1 | 2023 | 865 | 0.120 |
Why?
| | Visual Acuity | 1 | 2019 | 489 | 0.110 |
Why?
| | Maternal-Fetal Exchange | 1 | 2016 | 169 | 0.110 |
Why?
| | Cilia | 1 | 2017 | 173 | 0.110 |
Why?
| | Cesarean Section | 3 | 2024 | 224 | 0.110 |
Why?
| | Blood Flow Velocity | 1 | 2015 | 413 | 0.100 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2019 | 1217 | 0.100 |
Why?
| | Cell Cycle | 1 | 2017 | 596 | 0.100 |
Why?
| | Abruptio Placentae | 2 | 2024 | 6 | 0.100 |
Why?
| | Growth Disorders | 1 | 2014 | 86 | 0.100 |
Why?
| | Vascular Resistance | 1 | 2015 | 367 | 0.100 |
Why?
| | Infant, Premature | 2 | 2017 | 611 | 0.100 |
Why?
| | Fetal Distress | 1 | 2012 | 14 | 0.090 |
Why?
| | Ovarian Diseases | 1 | 2012 | 13 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2010 | 1455 | 0.090 |
Why?
| | Oogenesis | 1 | 2012 | 19 | 0.090 |
Why?
| | Ovulation | 1 | 2012 | 41 | 0.090 |
Why?
| | Eicosanoids | 1 | 2012 | 58 | 0.090 |
Why?
| | Estrogen Antagonists | 1 | 2012 | 48 | 0.090 |
Why?
| | Placentation | 1 | 2012 | 53 | 0.090 |
Why?
| | Pregnancy Proteins | 1 | 2012 | 35 | 0.090 |
Why?
| | Chorioamnionitis | 1 | 2012 | 45 | 0.090 |
Why?
| | Muscle Tonus | 1 | 2011 | 24 | 0.090 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2017 | 410 | 0.090 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2011 | 74 | 0.090 |
Why?
| | Retrospective Studies | 3 | 2025 | 17066 | 0.090 |
Why?
| | Parturition | 1 | 2012 | 69 | 0.090 |
Why?
| | Metabolic Networks and Pathways | 1 | 2012 | 187 | 0.080 |
Why?
| | Ultrasonography | 1 | 2015 | 770 | 0.080 |
Why?
| | Animals | 7 | 2023 | 38058 | 0.080 |
Why?
| | Large Neutral Amino Acid-Transporter 1 | 1 | 2010 | 17 | 0.080 |
Why?
| | Vasoconstriction | 1 | 2011 | 217 | 0.080 |
Why?
| | Myometrium | 1 | 2010 | 38 | 0.080 |
Why?
| | Placenta Growth Factor | 2 | 2022 | 26 | 0.080 |
Why?
| | Leiomyoma | 1 | 2010 | 59 | 0.080 |
Why?
| | Apoptosis | 1 | 2018 | 2430 | 0.080 |
Why?
| | Prospective Studies | 4 | 2024 | 7990 | 0.080 |
Why?
| | Child, Preschool | 2 | 2024 | 11787 | 0.080 |
Why?
| | Paracrine Communication | 1 | 2010 | 67 | 0.070 |
Why?
| | Thromboxanes | 1 | 2009 | 13 | 0.070 |
Why?
| | Uterine Neoplasms | 1 | 2010 | 96 | 0.070 |
Why?
| | Blotting, Western | 1 | 2011 | 1187 | 0.070 |
Why?
| | Molecular Targeted Therapy | 1 | 2012 | 432 | 0.070 |
Why?
| | Neoplasm Proteins | 1 | 2012 | 442 | 0.070 |
Why?
| | Myocytes, Smooth Muscle | 1 | 2010 | 266 | 0.070 |
Why?
| | Vasodilation | 1 | 2011 | 523 | 0.070 |
Why?
| | Glucocorticoids | 1 | 2012 | 535 | 0.070 |
Why?
| | Retinoid X Receptor alpha | 1 | 2007 | 3 | 0.070 |
Why?
| | Progesterone Congeners | 1 | 2007 | 14 | 0.070 |
Why?
| | Retinoic Acid Receptor alpha | 1 | 2007 | 16 | 0.070 |
Why?
| | Receptors, Retinoic Acid | 1 | 2007 | 42 | 0.060 |
Why?
| | Immunohistochemistry | 1 | 2011 | 1716 | 0.060 |
Why?
| | Aromatase | 1 | 2007 | 32 | 0.060 |
Why?
| | Promoter Regions, Genetic | 1 | 2012 | 1257 | 0.060 |
Why?
| | Cell Differentiation | 2 | 2017 | 2050 | 0.060 |
Why?
| | Immunoblotting | 1 | 2007 | 300 | 0.060 |
Why?
| | Breast Neoplasms | 2 | 2012 | 2452 | 0.060 |
Why?
| | Fluorescent Antibody Technique | 1 | 2007 | 370 | 0.060 |
Why?
| | Databases, Factual | 1 | 2011 | 1486 | 0.060 |
Why?
| | Endometrial Neoplasms | 1 | 2007 | 208 | 0.050 |
Why?
| | Arterial Pressure | 1 | 2024 | 136 | 0.050 |
Why?
| | Kidney Tubules, Proximal | 1 | 2023 | 130 | 0.050 |
Why?
| | RNA, Messenger | 2 | 2010 | 2832 | 0.050 |
Why?
| | Kidney | 2 | 2023 | 1495 | 0.050 |
Why?
| | Mice | 3 | 2023 | 18339 | 0.050 |
Why?
| | Biomarkers | 3 | 2022 | 4271 | 0.050 |
Why?
| | Male | 6 | 2025 | 72315 | 0.050 |
Why?
| | Vascular Endothelial Growth Factors | 1 | 2022 | 80 | 0.050 |
Why?
| | Triage | 1 | 2024 | 249 | 0.040 |
Why?
| | Administration, Oral | 1 | 2024 | 847 | 0.040 |
Why?
| | Fetal Hypoxia | 1 | 2022 | 56 | 0.040 |
Why?
| | Virus Internalization | 1 | 2021 | 65 | 0.040 |
Why?
| | Ovarian Neoplasms | 1 | 2007 | 586 | 0.040 |
Why?
| | Middle Aged | 4 | 2025 | 35875 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 484 | 0.040 |
Why?
| | Length of Stay | 1 | 2025 | 1337 | 0.040 |
Why?
| | Child | 1 | 2019 | 22633 | 0.040 |
Why?
| | Prevalence | 1 | 2025 | 2834 | 0.030 |
Why?
| | Synthetic Biology | 1 | 2017 | 15 | 0.030 |
Why?
| | Altitude | 1 | 2022 | 473 | 0.030 |
Why?
| | Patient Acceptance of Health Care | 1 | 2024 | 885 | 0.030 |
Why?
| | Zinc Finger Protein GLI1 | 1 | 2017 | 26 | 0.030 |
Why?
| | Transcriptome | 1 | 2023 | 1045 | 0.030 |
Why?
| | Phosphatidylinositol 4,5-Diphosphate | 1 | 2017 | 32 | 0.030 |
Why?
| | Granulocyte Colony-Stimulating Factor | 1 | 2017 | 89 | 0.030 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2017 | 56 | 0.030 |
Why?
| | NIH 3T3 Cells | 1 | 2017 | 148 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2022 | 2115 | 0.030 |
Why?
| | Pregnancy Complications, Infectious | 1 | 2021 | 428 | 0.030 |
Why?
| | Microvilli | 1 | 2016 | 75 | 0.030 |
Why?
| | Proof of Concept Study | 1 | 2016 | 85 | 0.030 |
Why?
| | Infant, Extremely Premature | 1 | 2017 | 67 | 0.030 |
Why?
| | Body Mass Index | 1 | 2024 | 2438 | 0.030 |
Why?
| | Models, Animal | 1 | 2017 | 392 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2016 | 246 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 324 | 0.030 |
Why?
| | Microscopy, Confocal | 1 | 2016 | 321 | 0.030 |
Why?
| | Gene Regulatory Networks | 1 | 2017 | 318 | 0.030 |
Why?
| | United States | 2 | 2025 | 15966 | 0.030 |
Why?
| | Aged | 2 | 2025 | 25913 | 0.030 |
Why?
| | Equipment Design | 1 | 2016 | 530 | 0.030 |
Why?
| | Actins | 1 | 2017 | 425 | 0.030 |
Why?
| | Single-Cell Analysis | 1 | 2017 | 358 | 0.030 |
Why?
| | Adolescent | 1 | 2013 | 22428 | 0.020 |
Why?
| | Tissue Engineering | 1 | 2017 | 442 | 0.020 |
Why?
| | Time Factors | 1 | 2024 | 7173 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2023 | 4557 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2025 | 8265 | 0.020 |
Why?
| | Cardiotocography | 1 | 2012 | 5 | 0.020 |
Why?
| | Fetal Monitoring | 1 | 2012 | 20 | 0.020 |
Why?
| | Young Adult | 2 | 2024 | 14105 | 0.020 |
Why?
| | Emergency Service, Hospital | 1 | 2024 | 2310 | 0.020 |
Why?
| | Heart Rate, Fetal | 1 | 2012 | 31 | 0.020 |
Why?
| | Genomics | 1 | 2017 | 834 | 0.020 |
Why?
| | Microarray Analysis | 1 | 2012 | 117 | 0.020 |
Why?
| | Cell Line | 1 | 2016 | 2882 | 0.020 |
Why?
| | Mifepristone | 1 | 2010 | 64 | 0.020 |
Why?
| | Hormone Antagonists | 1 | 2010 | 34 | 0.020 |
Why?
| | Infant | 1 | 2024 | 10034 | 0.020 |
Why?
| | CpG Islands | 1 | 2010 | 165 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 11679 | 0.020 |
Why?
| | Acute Disease | 1 | 2012 | 1030 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2947 | 0.020 |
Why?
| | Dinoprostone | 1 | 2008 | 178 | 0.020 |
Why?
| | Cell Survival | 1 | 2010 | 1098 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2010 | 2027 | 0.010 |
Why?
| | Gene Expression Profiling | 1 | 2012 | 1782 | 0.010 |
Why?
| | DNA Methylation | 1 | 2010 | 681 | 0.010 |
Why?
| | Severity of Illness Index | 1 | 2012 | 2925 | 0.010 |
Why?
| | Transcription Factors | 1 | 2008 | 1741 | 0.010 |
Why?
| | Inflammation | 1 | 2008 | 2878 | 0.010 |
Why?
|
|
Su's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|